EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long‐term results from the phase I/II COMPOSER trial

Alexander Röth, Satoshi Ichikawa, Yoshikazu Ito, Jin Seok Kim, Zsolt Nagy, Naoshi Obara, Jens Panse iD, Hubert Schrezenmeier, Simona Sica, Juliette Soret, Kensuke Usuki, Sung-Soo Yoon und 7 weitere

European Journal of Haematology · 2023

DOI: 10.1111/ejh.14011 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Alexander Röth und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germa…. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: F. Hoffmann-La Roche, Ltd, Chugai Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study reports long‐term outcomes from the open‐label extension (OLE) period of the Phase I/II COMPOSER trial (NCT03157635) that evaluated crovalimab in patients with paroxysmal nocturnal haemoglobinuria, who were treatment‐naive or switched from eculizumab at enrolment.

Methods

COMPOSER consists of four sequential parts followed by the OLE. The primary OLE objective was to assess long‐term crovalimab safety, with a secondary objective to assess crovalimab pharmacokinetics and pharmacodynamics. Exploratory efficacy endpoints included change in lactate dehydrogenase (LDH), transfusion avoidance, haemoglobin stabilisation and breakthrough haemolysis (BTH).

Results

A total 43 of 44 patients entered the OLE after completing the primary treatment period. Overall, 14 of 44 (32%) experienced treatment‐related adverse events. Steady state exposure levels of crovalimab and terminal complement inhibition were maintained over the OLE. During the OLE, mean normalised LDH was generally maintained at ≤1.5× upper limit of normal, transfusion avoidance was achieved in 83%–92% of patients and haemoglobin stabilisation was reached in 79%–88% of patients across each 24‐week interval. Five BTH events occurred with none leading to withdrawal.

Conclusions

Over a 3‐year median treatment duration, crovalimab was well tolerated and sustained C5 inhibition was achieved. Intravascular haemolysis control, haemoglobin stabilisation and transfusion avoidance were maintained, signifying long‐term crovalimab efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemoglobinuria, ParoxysmalHumansAntibodies, MonoclonalBlood TransfusionHemoglobinsDuration of TherapyHemolysisL-Lactate Dehydrogenase

Stichwörter der Autor:innen

bone marrow failure disorderscomplement C5complement inhibitoreculizumabparoxysmal nocturnal haemoglobinuria

Substanzen

Antibodies, MonoclonalHemoglobinsL-Lactate Dehydrogenase

Autor:innen und Institutionen

  • Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
  • Department of Hematology, Tohoku University Hospital, Miyagi, Japan.
  • Department of Hematology, Tokyo Medical University, Tokyo, Japan.
  • Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea.
  • Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary.
  • Department of Hematology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

ORCID-Profile: Jens Panse

Förderung

  • F. Hoffmann-La Roche, Ltd
  • Chugai Pharmaceutical

Zitieren

APA

Röth, A., Ichikawa, S., Ito, Y., Kim, J. S., Nagy, Z., Obara, N., Panse, J., Schrezenmeier, H., Sica, S., Soret, J., Usuki, K., Yoon, S. S., Balachandran, N., Buri, M., Lundberg, P., Patel, H., Shinomiya, K., Sostelly, A., & Nishimura, J. I. (2023). Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long‐term results from the phase I/II COMPOSER trial. European Journal of Haematology. https://doi.org/10.1111/ejh.14011

Vancouver

Röth A, Ichikawa S, Ito Y, Kim JS, Nagy Z, Obara N, et al. Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long‐term results from the phase I/II COMPOSER trial. European Journal of Haematology. 2023. doi:10.1111/ejh.14011

BibTeX
@article{Rth2023,
  author = {Röth, Alexander and Ichikawa, Satoshi and Ito, Yoshikazu and Kim, Jin Seok and Nagy, Zsolt and Obara, Naoshi and Panse, Jens and Schrezenmeier, Hubert and Sica, Simona and Soret, Juliette and Usuki, Kensuke and Yoon, Sung-Soo and Balachandran, Nadiesh and Buri, Muriel and Lundberg, Pontus and Patel, Himika and Shinomiya, Kenji and Sostelly, Alexandre and Nishimura, Jun-Ichi},
  title = {Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long‐term results from the phase I/II COMPOSER trial},
  journal = {European Journal of Haematology},
  year = {2023},
  doi = {10.1111/ejh.14011}
}
Kostenlos starten →